Recent Updates
Recently added Catalysts

PRV-300

Phase 1

Ulcerative Colitis | Monoclonal antibody | Immunology |Sanofi|Last Updated: Feb 12, 2020

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment37
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03849599A Study to Evaluate the Safety of PRV-300 in Adult Subjects With Moderately to Severely Active Ulcerative ColitisPHASE1 COMPLETED 37Feb 1, 2018Feb 1, 2019Feb 12, 2020 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
PRV-300BIOLOGICALTreatment
PlaceboBIOLOGICALControl
Unlock Study Design Details